| Symbol | A |
|---|---|
| Name | AGILENT TECHNOLOGIES, INC. |
| Sector | INDUSTRIALS |
| Region | North America |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Address | 5301 STEVENS CREEK BOULEVARD, SANTA CLARA, California, 95051, United States |
| Telephone | +1 800 227-9770 |
| Fax | — |
| — | |
| Website | https://www.agilent.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001090872 |
| Description | Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. Additional info from NASDAQ: |
Agilent Technologies, Inc. - Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation
Read moreAgilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation
Read moreAgilent Technologies, Inc. - Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
Read moreAgilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
Read moreDirector Dolsten Mikael 🔴 sold 1.6K shares of AGILENT TECHNOLOGIES, INC. (A) at $135.42 Transaction Date: May 29, 2026 | Filing ID: 000057
Read more📋 Dolsten Mikael (Director) plans to sell 2K shares of AGILENT TECHNOLOGIES, INC. (at $135.42 each, total $217K) Filed: May 29, 2026 | ID: 004157
Read moreNew Form SD - AGILENT TECHNOLOGIES, INC. <b>Filed:</b> 2026-05-29 <b>AccNo:</b> 0001193125-26-248281 <b>Size:</b> 667 KB
Read moreAgilent Technologies, Inc. - Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory
Read moreAgilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory
Read more(30% Negative) AGILENT TECHNOLOGIES, INC. (A) Reports Q2 2026 Financial Results
Read more